Common questions
What is the tesamorelin and ipamorelin blend?
It is a combination of two growth hormone compounds. Tesamorelin is a GHRH analog and ipamorelin is a ghrelin-mimetic GH secretagogue. Together they target two different receptors that feed the same growth hormone pulse. The blend is sold for research use only and is not FDA-approved as a combination product.
What is the tesamorelin ipamorelin blend dosage per day?
Common research-planning structures use one subcutaneous dose per day with gradual titration. For reference, tesamorelin's FDA label dose alone is 2 mg/day (or 1.28 mg/day for the EGRIFTA WR formulation), and ipamorelin has been studied around 100–300 mcg per dose. This is not a dosing recommendation. Use the calculator for your exact vial.
What is the difference between the 10/3 and 5/5 blend?
The 10/3 vial holds 10 mg tesamorelin and 3 mg ipamorelin (13 mg total), so it is GHRH-dominant. The 5/5 vial holds 5 mg of each (10 mg total) for a balanced 1:1 ratio. The ratio changes how much of each compound is in every draw, so reconstitute and measure with your specific ratio in mind.
How do you reconstitute the tesamorelin ipamorelin blend?
Add 3.0 mL bacteriostatic water to the 3 mL vial, aiming down the wall, then swirl gently until clear. A 10/3 vial becomes about 4.33 mg/mL total; a 5/5 vial becomes about 3.33 mg/mL total.
Open the reconstitution calculator →Can you take tesamorelin and ipamorelin together?
They are commonly combined in research planning because they act on two different GH pathways, and GHRH-plus-secretagogue pairings have amplified GH pulses in human secretagogue studies. However, no human trial has tested this specific blend, so the combined safety and effect profile is not established. This is educational information, not medical advice.
When is the blend usually taken?
Once-daily evening or bedtime dosing is the most common structure, chosen to track the body's natural nighttime GH release. Some separate-vial users place ipamorelin earlier in the day. Timing is a planning convention here, not a medical instruction.
How long is a typical cycle?
Research-planning cycles commonly run 8–16 weeks followed by 4–8 weeks off, a convention used to limit receptor desensitization. There is no established cycle length for the blend specifically.
Is the tesamorelin ipamorelin blend FDA-approved?
No. As of June 2026, tesamorelin is FDA-approved only for HIV-associated lipodystrophy (sold as EGRIFTA WR and EGRIFTA SV), ipamorelin is not FDA-approved, and the blend is not FDA-approved. It is sold for research use only.